Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials
R Ossenkoppele, R van der Kant… - The Lancet …, 2022 - thelancet.com
Background Deposition of tau aggregates is a pathological hallmark of Alzheimer's disease
that is closely linked both spatially and temporally to emergence of neurodegeneration and …
that is closely linked both spatially and temporally to emergence of neurodegeneration and …
The probabilistic model of Alzheimer disease: the amyloid hypothesis revised
The current conceptualization of Alzheimer disease (AD) is driven by the amyloid
hypothesis, in which a deterministic chain of events leads from amyloid deposition and then …
hypothesis, in which a deterministic chain of events leads from amyloid deposition and then …
Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline
A major unanswered question in the dementia field is whether cognitively unimpaired
individuals who harbor both Alzheimer's disease neuropathological hallmarks (that is …
individuals who harbor both Alzheimer's disease neuropathological hallmarks (that is …
Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer's disease
An unresolved question for the understanding of Alzheimer's disease (AD) pathophysiology
is why a significant percentage of amyloid-β (Aβ)-positive cognitively unimpaired (CU) …
is why a significant percentage of amyloid-β (Aβ)-positive cognitively unimpaired (CU) …
Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility
Well-authenticated biomarkers can provide critical insights into the biological basis of
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …
Biomarkers for neurodegenerative diseases
O Hansson - Nature medicine, 2021 - nature.com
Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup in
the clinic but also to facilitate the development and monitoring of effective disease-modifying …
the clinic but also to facilitate the development and monitoring of effective disease-modifying …
Microglial activation and tau propagate jointly across Braak stages
Compelling experimental evidence suggests that microglial activation is involved in the
spread of tau tangles over the neocortex in Alzheimer's disease (AD). We tested the …
spread of tau tangles over the neocortex in Alzheimer's disease (AD). We tested the …
Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology
The quantification of phosphorylated tau in biofluids, either cerebrospinal fluid (CSF) or
plasma, has shown great promise in detecting Alzheimer's disease (AD) pathophysiology …
plasma, has shown great promise in detecting Alzheimer's disease (AD) pathophysiology …
Biomarker modeling of Alzheimer's disease using PET-based Braak staging
Gold-standard diagnosis of Alzheimer's disease (AD) relies on histopathological staging
systems. Using the topographical information from [18F] MK6240 tau positron-emission …
systems. Using the topographical information from [18F] MK6240 tau positron-emission …
Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid …
Importance Tau positron emission tomography (PET) tracers have proven useful for the
differential diagnosis of dementia, but their utility for predicting cognitive change is unclear …
differential diagnosis of dementia, but their utility for predicting cognitive change is unclear …